Gornitzky represented Oppenheimer in the deal.MediWound Ltd., a biopharmaceutical company, executed a U.S. $10 million underwritten follow-on public offering of ordinary shares on Nasdaq. MediWound develops, manufactures and commercializes…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
